comparemela.com

Latest Breaking News On - Arbutus biopharma - Page 1 : comparemela.com

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by FourWorld Capital Management LLC

FourWorld Capital Management LLC lessened its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 18.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,090,851 shares of the biopharmaceutical company’s stock after selling 251,056 shares during the quarter. Arbutus Biopharma comprises approximately 1.8% of FourWorld Capital Management LLC’s investment portfolio, making the […]

China
United-states
Arbutus-biopharma-co
Holdings-channel
Barclays-plc
Arbutus-biopharma-corporation
Sg-americas-securities
Nasdaq
Fourworld-capital-management
Path-wealth-partners
China-universal-asset-management-co

FourWorld Capital Management LLC Sells 251,056 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

FourWorld Capital Management LLC reduced its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,090,851 shares of the biopharmaceutical company’s stock after selling 251,056 shares during the quarter. Arbutus Biopharma […]

United-states
China
Path-wealth-partners
China-universal-asset-management-co
Arbutus-biopharma-company-profile
Arbutus-biopharma-co
Barclays-plc
Arbutus-biopharma-corporation
Sg-americas-securities
Nasdaq
Fourworld-capital-management

Drug Delivery Technologies Market Growth and Status Explored in - 博客

Drug Delivery Technologies Market Growth and Status Explored in - 博客
wenxuecity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wenxuecity.com Daily Mail and Mail on Sunday newspapers.

South-korea
Australia
South-africa
Germany
Brazil
France
China
Canada
Saudi-arabia
Japan
Italy
United-states

Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy?

Moderna (NASDAQ:MRNA) stock has collapsed from its all-time high. However, the company is once again on the move — in a good way. The stock is up 68% over the past six months, with partnerships around artificial intelligence (AI) and positive cancer trial data garnering investor interest. Personally, though, I’m still unconvinced that these developments make MRNA stock a buy and require more data before I make a decision. For now, I remain neutral. MRNA stock has fallen significantly from its al

United-states
Meklit-workneh
Genevant-sciences
Clinical-development-at-moderna
Trademark-office
Openai-partnership
Clinical-development
Arbutus-biopharma
United-states-patent
Moderna-stock
Moderate-buy

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New-jersey
United-states
United-kingdom
Delaware
Michaelj-mcelhaugh
Chris-anzalone
Joseph-kaplan
Frank-torti
Moderna-spikevax
Arbutus-biopharma-corporation
Us-district-court
Whitefort-capital-master-fund
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.